Top Ten Pitfalls to New Medical Device Launches
It is not uncommon for a new medical device to fail to initially live up to projected sales expectations. Early disappointing product sales can produce a hole that a company can spend a long time trying to dig its way out of, having to battle a declining stock price, decreased investor confidence, lower company valuations, and diminished access to capital. The end result may be that both the product and the company are never able to fully recover from the early set-back. Many initial disappointing product roll-outs can be attributed to problems that commonly confront device companies. Product companies have adopted successful strategies to anticipate and overcome many of these issues, and thereby increase the chances of a new product coming strong out-of-the blocks.
You may also be interested in...
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.
908 Devices, Zimmer Biomet and Ortho Clinical Diagnostics have all appointed new directors, Biolase promotes executive vice president to chief executive officer role, and more.
The Swedish liquid biopsy start-up expects to be the first company to secure US FDA approval for a metabolism-based urine test for the early detection of kidney cancer in post-surgery patients.